Merck gets dueling analyst calls after vaccine data rally
Merck draws mixed analyst action after promising cancer vaccine results lifted shares almost 13% yesterday, with RBC Capital Markets downgrading to hold and Morgan Stanley upgrading to buy.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.